Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packed in an emergency kit, for the treatment of severe hypoglycemia (very low blood sugar), which may occur in patients with diabetes mellitus. The drug is also indicated as a diagnostic aid in the radiologic examination of the stomach, duodenum (the first part of the small intestine beyond the stomach), small bowel and colon when diminished intestinal motility (reduced ability to move) would be advantageous.
Severe hypoglycemia occurs when a patient’s blood glucose falls to a level where he or she becomes confused or unconscious, or suffers from other symptoms which require assistance from another person to treat. Generally, severe hypoglycemia occurs in people with diabetes that are using insulin treatment.
Glucagon for injection has been approved for use in the U.S. for more than 20 years, but until today, there has been no approved generic of this important drug that can save the lives of people who may experience the serious condition of very low blood sugar. Today’s approval reflects the FDA’s continued commitment to advancing patient access to lower-cost, high-quality generic drug products that are as safe and effective as their brand name counterparts. Supporting development and expanding opportunities to bring generic copies of complex drugs, like glucagon, to the market has been a major focus of our efforts to improve competition and help lower drug prices.”Sally Choe, Ph.D., Director, Office of Generic Drugs, FDA’s Center for Drug Evaluation and Research
Glucagon for injection has been approved for use in the U.S. for more than 20 years, but until today, there has been no approved generic of this important drug that can save the lives of people who may experience the serious condition of very low blood sugar. Today’s approval reflects the FDA’s continued commitment to advancing patient access to lower-cost, high-quality generic drug products that are as safe and effective as their brand name counterparts. Supporting development and expanding opportunities to bring generic copies of complex drugs, like glucagon, to the market has been a major focus of our efforts to improve competition and help lower drug prices.”
Sally Choe, Ph.D., Director, Office of Generic Drugs, FDA’s Center for Drug Evaluation and Research
The generic glucagon for injection is a synthetic version of human glucagon. Glucagon is a hormone that causes the liver to rapidly increase glucose levels. This hormone also slows down motion of the gastrointestinal tract. The most common side effects associated with glucagon for injection are nausea and vomiting, a temporary increase in heart rate, as well as redness and swelling of the injection site.
The FDA regularly takes steps to help guide business through the development process for generic drug products, such as complex products such as glucagon. The evolution of complex products can be more difficult because of their complicated active ingredient, formulation, or mode of delivery. As a result, many complex drugs lack generic competition even after patents and exclusivities no longer block generic approval.
The FDA maintains a list of off-patent, off-exclusivity drug products with no approved generic to improve transparency and promote the development and submission of applications for drugs with limited competition. Glucagon is included on this list. The FDA also prioritizes the review of submissions for generic medications for which there are fewer than three approved generics of the reference listed drug (RLD) and for which there are no blocking patents or exclusivities on the RLD.
Under the Generic Drug User Fee Amendments (GDUFA), individual companies can meet the FDA as part of its pre-Abbreviated New Drug Application (ANDA) program to support the development of such complex generic drug products.
The FDA requires sponsors to submit appropriate data and information to demonstrate that complicated generic drug products meet the agency’s rigorous approval standards. These standards ensure that quality generic drug products are as safe and effective as their brand name counterparts.
Addressing the challenges linked to complex generics, and encouraging more generic competition to these medicines, is a key part of the FDA’s Drug Contest Action Plan, and the agency’s efforts to promote patient access and more affordable medicines.
The FDA granted approval of the generic glucagon for injection to Amphastar Pharmaceuticals, Inc. of Rancho Cucamonga, Calif..
U.S. Food and Drug Administration
